FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 227 filers reported holding FATE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,162 | -64.7% | 7,154 | 0.0% | 0.00% | – |
| Q2 2023 | $34,482 | -12.4% | 7,154 | 0.0% | 0.00% | – |
| Q1 2023 | $39,347 | -41.8% | 7,154 | -39.5% | 0.00% | – |
| Q4 2022 | $67,599 | -96.5% | 11,818 | -85.6% | 0.00% | -100.0% |
| Q3 2022 | $1,929,000 | -74.0% | 81,848 | -65.3% | 0.00% | -83.3% |
| Q2 2022 | $7,427,000 | -47.5% | 235,693 | -34.1% | 0.01% | -40.0% |
| Q1 2022 | $14,148,000 | -12.0% | 357,539 | -6.2% | 0.01% | 0.0% |
| Q4 2021 | $16,084,000 | -32.1% | 381,134 | -4.6% | 0.01% | -41.2% |
| Q3 2021 | $23,688,000 | -33.2% | 399,654 | -2.2% | 0.02% | -32.0% |
| Q2 2021 | $35,453,000 | – | 408,487 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |